Hess E J, Albers L J, Le H, Creese I
J Pharmacol Exp Ther. 1986 Sep;238(3):846-54.
Chronic treatment of rats with SCH23390 (0.5 mg/kg/day s.c.), a D1 dopamine receptor antagonist, for 21 days resulted in an increase in D1 dopamine receptors but produced no change in D2 dopamine receptors. During habituation to locomotor activity cages the rats treated chronically with SCH23390 showed significantly higher locomotor activity than controls treated chronically with saline. When injected with the selective D1 dopamine receptor agonist SKF38393 (3 mg/kg), rats treated chronically with SCH23390 showed significantly greater stereotypy and locomotor activity responses. Surprisingly, rats treated chronically with SCH23390 also showed significantly higher locomotor activity and stereotypy responses when treated with the selective D2 dopamine receptor agonist, quinpirole (LY171555) (0.3 mg/kg). These results indicate that a selective increase in D1 receptors may not be necessary, but is sufficient, to lead to an enhanced behavioral response to either selective D1 or D2 dopamine receptor agonists. If, indeed, an enhanced stereotypy and locomotor activity response to dopaminergic agonists in rats after a brief chronic treatment with a neuroleptic drug is predictive of tardive dyskinesia potential in the clinical setting, these results can suggest that SCH23390 may also induce tardive dyskinesia in humans. Adenylate cyclase activity stimulated by guanine nucleotides, forskolin or dopamine was enhanced after chronic treatment with SCH23390. However, dopamine-stimulated adenylate cyclase activity was not potentiated detectably by the increase in receptor number over the more general increase in guanine nucleotide-stimulated cyclic AMP production. Additionally, no change was observed in dopamine competition for [3H]SCH23390 binding, with dopamine's RH/RL ratio remaining unchanged.(ABSTRACT TRUNCATED AT 250 WORDS)
用D1多巴胺受体拮抗剂SCH23390(0.5毫克/千克/天,皮下注射)对大鼠进行21天的慢性治疗,导致D1多巴胺受体增加,但D2多巴胺受体无变化。在适应运动活动笼的过程中,长期用SCH23390治疗的大鼠表现出比长期用生理盐水治疗的对照大鼠明显更高的运动活性。当注射选择性D1多巴胺受体激动剂SKF38393(3毫克/千克)时,长期用SCH23390治疗的大鼠表现出明显更强的刻板行为和运动活性反应。令人惊讶的是,长期用SCH23390治疗的大鼠在用选择性D2多巴胺受体激动剂喹吡罗(LY171555)(0.3毫克/千克)治疗时,也表现出明显更高的运动活性和刻板行为反应。这些结果表明,D1受体的选择性增加可能不是必需的,但足以导致对选择性D1或D2多巴胺受体激动剂的行为反应增强。如果确实如此,在临床环境中,用抗精神病药物进行短暂慢性治疗后,大鼠对多巴胺能激动剂的刻板行为和运动活性反应增强可预测迟发性运动障碍的可能性,那么这些结果可能表明SCH23390也可能在人类中诱发迟发性运动障碍。用SCH23390进行慢性治疗后,鸟嘌呤核苷酸、福司可林或多巴胺刺激的腺苷酸环化酶活性增强。然而,与鸟嘌呤核苷酸刺激的环磷酸腺苷生成的更普遍增加相比,受体数量的增加并未明显增强多巴胺刺激的腺苷酸环化酶活性。此外, 未观察到多巴胺对[3H]SCH23390结合的竞争发生变化,多巴胺的RH/RL比值保持不变。(摘要截短于250字)